Therapy Areas: Inflammatory Diseases
Can-Fite reports preclinical data supporting Phase IIb pancreatic cancer study
17 August 2026 - Israel-based clinical-stage biotechnology company Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF), which develops small-molecule drugs for oncological and inflammatory disea...
AlzeCure completes QuantumCell transaction with USD12m upfront payment
12 August 2026 - Swedish biotech company AlzeCure Pharma AB (FN STO:ALZCUR) announced on Wednesday that it has received the full USD12m upfront payment from Danish biotech company QuantumCell ApS unde...
Graviton BioScience's Investigational New Drug (IND) application for GV101 cleared for Friedreich's ataxia treatment
12 August 2026 - Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse pipeline of therapeutics, including selective ROCK2 inhibitors for metabol...
Alfasigma to acquire Nordic Pharma, expanding specialty care portfolio
11 August 2026 - Italian pharmaceutical company Alfasigma S.p.A. announced on Tuesday that it has entered into an agreement with SEVER Life Sciences B.V. to acquire 100% of Nordic Group B.V. and its s...
Kodiak Sciences enrols first patients in KSI-501 Phase 3 ALTO trial in patients with diabetic macular oedema
11 August 2026 - Kodiak Sciences Inc (Nasdaq:KOD), a precommercial retina-focused biotechnology company, announced on Monday that the first patients have been enrolled in the global Phase 3 ALTO trial...
European Commission approves RINVOQ for severe alopecia areata
29 July 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Wednesday it has received European Commission approval for RINVOQ (upadacitinib) to treat adults and adolescents aged 12 and ove...